Condition

Chronic Obstructive Pulmonary Disease COPD

ClinicalTrials.gov condition label

Clinical trials8

Recruiting2

Common interventions14

Lead sponsors shown4

Clinical trials

8 shown

Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported OutcomesNCT07380711 · 2026-01-28

A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT07292714 · 2025-07-15

Realize the Current Situation of COPD Patients in ChinaNCT03131362 · 2017-06-30

Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseNCT03162055 · 2017-05-25

Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871NCT02971293 · 2016-12-15

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese MenNCT02645253 · 2016-01-12

A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance TherapyNCT02238483 · 2014-10-28

Pulmonary Rehabilitation: Effects on Cognitive Functioning, Mood, Anxiety, and Quality of Life in Patients With COPDNCT01682447 · 2011-01-01

Common interventions

PlaceboDRUG2 9MW1911DRUG1 AZD7594 inhalation powder (200 μg)DRUG1 AZD7594 inhalation powder (400 μg)DRUG1 AZD7594 placebo inhalation powderDRUG1 AZD7594 placebo pressurized inhalation suspensionDRUG1 AZD7594 pressurized inhalation suspension (200 μg)DRUG1 AZD7624 1.0 mgDRUG1 AZD8871 100 µgDRUG1 AZD8871 600 µgDRUG1 Extensive Pulmonary Rehabilitation ProgramOTHER1 Glycopyrronium/Formoterol FumarateDRUG1 Phase II placeboDRUG1 umeclidinium/vilanterolDRUG1

Leading sponsors

AstraZeneca5 Mabwell (Shanghai) Bioscience Co., Ltd.1 Sanofi1 Tilburg University1

Trial status mix

COMPLETED6

RECRUITING2

Phase mix

PHASE23

NA1

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.